LivaNova (NASDAQ:LIVN) Releases Earnings Results, Beats Expectations By $0.06 EPS

LivaNova (NASDAQ:LIVN) released its quarterly earnings data on Wednesday. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06, FiscalAI reports. The business had revenue of $360.90 million for the quarter, compared to analysts’ expectations of $354.31 million. LivaNova had a positive return on equity of 15.98% and a negative net margin of 16.12%.LivaNova’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.81 earnings per share. LivaNova updated its FY 2026 guidance to 4.150-4.250 EPS.

Here are the key takeaways from LivaNova’s conference call:

• The company reported double-digit organic revenue growth and 150 basis points of adjusted operating margin expansion in 2025, with strong cash generation and a 2026 revenue guide of +6% to +7% consistent with its Investor Day framework.
• LivaNova advanced its obstructive sleep apnea (OSA) program with a planned PMA approval for the clinical device in H1 2026, a follow-on MRI-compatible supplement and a commercial rollout targeting 2027, while highlighting the OSPREY RCT and the PolySync algorithm that management says can convert many non-responders.
• Epilepsy benefits from two near-term tailwinds: the CORE‑VNS clinical data
• Near‑term risks include third‑party component constraints for oxygenators, higher capital and R&D spend (2026 capex guidance ~$120M) to scale manufacturing and advance OSA, modest tariff exposure, and a reserved SNIA-related cash obligation (~$400M potential Q3 payment) that management says remains the company’s best estimate of the liability.

LivaNova Price Performance

NASDAQ LIVN traded up $0.94 on Wednesday, hitting $69.99. 794,831 shares of the company were exchanged, compared to its average volume of 694,501. LivaNova has a 1-year low of $32.48 and a 1-year high of $70.32. The firm has a 50 day moving average of $64.26 and a two-hundred day moving average of $58.73. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30. The company has a market cap of $3.82 billion, a P/E ratio of -17.49 and a beta of 0.97.

Institutional Investors Weigh In On LivaNova

Several hedge funds and other institutional investors have recently made changes to their positions in the company. State of Wyoming bought a new position in shares of LivaNova in the 2nd quarter valued at about $31,000. EverSource Wealth Advisors LLC lifted its holdings in LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares during the period. Quarry LP acquired a new stake in LivaNova during the 3rd quarter worth $36,000. UMB Bank n.a. lifted its stake in LivaNova by 22.6% in the fourth quarter. UMB Bank n.a. now owns 971 shares of the company’s stock valued at $60,000 after buying an additional 179 shares during the period. Finally, Johnson Financial Group Inc. bought a new stake in shares of LivaNova in the 3rd quarter valued at about $63,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LIVN has been the subject of a number of recent research reports. Barclays increased their price objective on shares of LivaNova from $58.00 to $67.00 and gave the company an “equal weight” rating in a research note on Friday, January 9th. KeyCorp began coverage on shares of LivaNova in a research report on Friday, December 19th. They issued an “overweight” rating and a $81.00 price target for the company. Mizuho lifted their price objective on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Piper Sandler reissued an “overweight” rating and issued a $85.00 target price on shares of LivaNova in a report on Thursday, February 19th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $66.00 target price on shares of LivaNova in a research report on Friday, January 9th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $73.00.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

Read More

• Five stocks we like better than LivaNova
• The gold chart Wall Street is terrified of…
• America’s 1776 happening again
• Buy this Gold Stock Before May 2026
• This makes me furious
• What a Former CIA Agent Knows About the Coming Collapse